ArticleFrontiers in endocrinology2026
Balancing oncologic risk and fertility potential: a single-center study on Turner syndrome patients with Y chromosome material.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Turner Syndrome (TS) is a chromosomal disorder characterized by partial or complete monosomy of the X chromosome. Approximately 5-10% of patients with TS harbor Y chromosome material, which is associated with an increased risk of gonadoblastoma and other gonadal malignancies. However, the indications and optimal timing of prophylactic gonadectomy remain controversial, particularly in asymptomatic individuals, because a subset of TS patients with Y chromosome material may retain residual gonadal function and fertility potential. This study aimed to determine the prevalence of Y chromosome material in TS patients, evaluate the associated risk of gonadal tumors, and assess fertility potential using molecular genetic techniques, thereby providing evidence to inform individualized clinical decision-making. Methods: A total of 224 patients with TS diagnosed between 2016 and 2024 were enrolled. Molecular genetic techniques were utilized to identify Y-sequences. In Y-positive cases, we systematically analyzed gonadal tumor incidence via histopathology, endocrine profiles (FSH, LH, AMH), and pelvic imaging findings. Results: Y-chromosome material was identified in 11.6% (26/224) of patients. Among the 16 who underwent surgery, gonadal tumors were pathologically confirmed in 4 cases (25.0%), including a tumor in a patient with cryptic Y-material undetected by karyotyping. Importantly, preoperative pelvic ultrasonography failed to detect any definite masses in these tumor-positive cases. Endocrine profiling revealed an age-dependent decline in gonadal function: while prepubertal patients maintained uncertain endocrine activity, those in or beyond puberty exhibited hypergonadotropic hypogonadism. AMH levels indicated that the window for fertility potential is narrow and typically closes by early adolescence. Conclusion: TS patients harboring Y-chromosome material face a significant risk of malignancy that cannot be reliably excluded by imaging alone. Our findings reinforce the necessity of early prophylactic gonadectomy. While individualized management may consider fertility preservation in select prepubertal patients, the rapid depletion of ovarian reserve necessitates proactive clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.